Crossmark

Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care—a systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1007/s00592-025-02534-y

Published Online: 2025-06-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yan, Kangling https://orcid.org/0009-0009-8652-1395
Yu, Haichuan

Blaise, Benoît
Funding

Funding for this research was provided by:

University of Sydney
License Information

Text and Data Mining valid from 2025-06-05

Version of Record valid from 2025-06-05
More Information

Article History

Received: 4 December 2024

Accepted: 7 May 2025

First Online: 5 June 2025

Declarations

:

: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Document is current

Any future updates will be listed below